PDS Biotechnology Corporation (PDSB) News

PDS Biotechnology Corporation (PDSB): $3.69

0.04 (+1.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PDSB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter PDSB News Items

PDSB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PDSB News Highlights

  • PDSB's 30 day story count now stands at 8.
  • Over the past 22 days, the trend for PDSB's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • PDS, DRUG and ITT are the most mentioned tickers in articles about PDSB.

Latest PDSB News From Around the Web

Below are the latest news stories about PDS Biotechnology Corp that investors may wish to consider to help them evaluate PDSB as an investment opportunity.

PDS Biotech posts early safety data for PDS0101, Keytruda combo in head and neck cancer

After four straight sessions of declines, the shares of PDS Biotechnology (PDSB +3.0%) are trading higher on Thursday after the clinical-stage biotech company reported initial safety data for an experimental drug combination from a mid-stage study in head and neck cancer. The Phase 2 VERSATILE-002 trial was designed to assess...

Seeking Alpha | February 24, 2022

PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium

Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity FLORHAM PARK, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based o

Yahoo | February 24, 2022

PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers

PDS Biotechnology (PDSB) is based in New Jersey. For this post, I will focus on the Versamune platform of the company in oncology. PDS Biotechnology's Versamune platform leverages the body's own defense systems to prime antigen-specific CD8+ killer T cells and memory T cells. The company is combining its proprietary...

Bhavneesh Sharma on Seeking Alpha | February 22, 2022

H.C. Wainwright Sticks to Its Buy Rating for PDS Biotechnology (PDSB)

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on PDS Biotechnology (PDSB – Research Report) today and set a price target of $15.00. The company's shares closed last Tuesday at $6.96. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -17.4% and a 24.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. PDS Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $15.00, representing an 113.7% upside.

Catie Powers on TipRanks | February 15, 2022

PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck Cancer

The study evaluates PDS0101 with and without KEYTRUDA® prior to surgery for HPV-associated oropharyngeal cancer FLORHAM PARK, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced the initiation of an Investigator-Initiated Trial (ITT), MC200710, for P

Yahoo | February 15, 2022

PDS Biotechnology (NASDAQ:PDSB) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | February 11, 2022

Oppenheimer Says There’s Room for at Least 60% Gains in These 2 Stocks

The stock market has always been a volatile environment – but the last several weeks have seen an increase in that phenomenon. The bull market of 2021 shifted into reverse in January, and increased intraday swings, along with a partial reversal of losses, have been the order of the day in February. Unsurprisingly, much of the market’s currently unsettled character can be attributed to set of conflicting currents that are pushing in multiple directions at once. A new report on market and economic

Yahoo | February 9, 2022

PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA® (pembrolizumab) in Advanced Head and Neck Cancer

Achievement of initial efficacy milestone allows full enrollment of checkpoint inhibitor naïve cohortFLORHAM PARK, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced its VERSATILE-002 Phase 2 study for the treatment of advanced human papillomavirus

Yahoo | February 2, 2022

Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Icon (ICLR) and PDS Biotechnology (PDSB)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Labs (ABT – Research Report), Icon (ICLR – Research Report) and PDS Biotechnology (PDSB – Research Report) with bullish sentiments. Abbott Labs (ABT) Morgan Stanley analyst Cecilia Furlong maintained a Buy rating on Abbott Labs today and set a price target of $151.00. The company's shares closed last Thursday at $122.04. According to TipRanks.

Brian Anderson on TipRanks | January 27, 2022

PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine

PDS0202 (Infectimune™ + COBRA Influenza Antigens) neutralized multiple strains of the flu and provided effective protection against infection in preclinical studiesFLORHAM PARK, N.J., Jan. 27, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced preclinical data for

Yahoo | January 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5176 seconds.